Form 4: Vanda Pharmaceuticals Director Sells 7,000 Shares Under Pre-Arranged Plan

Stephen Ray Mitchell, a Director at Vanda Pharmaceuticals Inc., sold 7,000 shares of common stock for approximately $32,130 under a Rule 10b5-1 trading plan.

Summary

• Stephen Ray Mitchell, a Director of Vanda Pharmaceuticals Inc. (VNDA), reported the sale of 7,000 shares of the company's common stock.
• The transaction occurred on June 13, 2025, at a weighted average price of $4.59 per share.
• The total value of the shares sold was approximately $32,130.
• The sale was conducted pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Mr. Mitchell beneficially owns 97,082 shares of Vanda Pharmaceuticals common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive because while it's a director selling shares, the explicit mention of it being under a Rule 10b5-1 plan indicates it was pre-scheduled and not based on new, non-public information, which mitigates negative investor perception.

Positives

• The transaction was made pursuant to a plan intended to satisfy Rule 10b5-1(c), which suggests the sale was pre-scheduled and not based on new, material non-public information, mitigating potential negative interpretations.

Negatives

• A director selling shares, even under a pre-arranged plan, reduces their direct ownership stake in the company.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategy.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• The sale of common stock by Stephen Ray Mitchell, a Director of Vanda Pharmaceuticals Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a signal, though the transaction was conducted under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not based on new, non-public information, potentially reducing negative impact on investor confidence.

Key Dates

Keywords

Vanda Pharmaceuticals, VNDA, Stephen Ray Mitchell, SEC Form 4, Insider Trading, Stock Sale, Director, Rule 10b5-1